Aurinia Pharmaceuticals Inc.’s recently made public that its Director Jayne David R.W. unloaded Company’s shares for reported $98334.0 on May 23. In the deal valued at $11.26 per share,8,733 shares were sold. As a result of this transaction, Jayne David R.W. now holds 49,310 shares worth roughly $ 0.47 million.
Then, MacKay-Dunn R. Hector sold 4,818 shares, generating $54,251 in total proceeds. Upon selling the shares at $11.26, the Director now owns 24,225 shares.
Before that, Leversage Jill sold 4,815 shares. Aurinia Pharmaceuticals Inc. shares valued at $54,217 were divested by the Director at a price of $11.26 per share. As a result of the transaction, Leversage Jill now holds 18,528 shares, worth roughly $0.18 million.
Oppenheimer downgraded its Aurinia Pharmaceuticals Inc. [AUPH] rating to a Perform from a an Outperform in a research note published on Friday.
Price Performance Review of AUPH
On Friday, Aurinia Pharmaceuticals Inc. [NASDAQ:AUPH] saw its stock jump 4.30% to $9.46. On the same session, the stock had its day’s lowest price of $9.08, but rose to a high of $9.57. Over the last five days, the stock has gained 3.28%. Aurinia Pharmaceuticals Inc. shares have risen nearly 118.98% since the year began. Nevertheless, the stocks have risen 28.53% over the past one year. While a 52-week high of $12.43 was reached on 07/28/23, a 52-week low of $4.07 was recorded on 01/03/23. SMA at 50 days reached $10.09, while 200 days put it at $8.94. A total of 1.26 million shares were traded, compared to the trading of 1.1 million shares in the previous session.
Levels Of Support And Resistance For AUPH Stock
The 24-hour chart illustrates a support level at 9.17, which if violated will result in even more drops to 8.88. On the upside, there is a resistance level at 9.66. A further resistance level may holdings at 9.86. The Relative Strength Index (RSI) on the 14-day chart is 46.62, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.12, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 45.63%. Stochastics %K at 31.39% indicates the stock is a holding.
How much short interest is there in Aurinia Pharmaceuticals Inc.?
A steep rise in short interest was recorded in Aurinia Pharmaceuticals Inc. stocks on Aug 14, 2023, dropping by 10000.0 shares to a total of 16.7 million shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 16.71 million shares. There was a decline of -0.06%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 11.68% of the overall stock float, the days-to-cover ratio (short ratio) fell to 6.02.
Aurinia Pharmaceuticals Inc. [AUPH] – Who Are The Largest Shareholders?
In filings from BlackRock Fund Advisors, it is revealed that the company now owns 6,990,867 shares, or roughly 4.89% of the outstanding AUPH shares. In other words, the investor’s shares have risen by 374,078 from its previous 13-F filing of 6616789.0. Additionally, Armistice Capital LLC increased 12.46% of its stake after which the total value it holdings stand at $54,333,360, while SSgA Funds Management, Inc. added 2.03% of its stake to hold $30.48 million in the firm. Over the last quarter, Goldman Sachs Asset Management LP purchased 711,140 shares of Aurinia Pharmaceuticals Inc., while Renaissance Technologies LLC bought -53,800 shares. At present, Geode Capital Management LLC is holding 1,410,766 shares valued at $16.34 million. Two Sigma Investments LP owned 1,368,171 shares of the company at the time of its most recent 13F filing, worth $15.84 million.
According to FactSet, Aurinia Pharmaceuticals Inc.’s share price will average $14.00 in the next year, based on opinions of analysts polled by the firm. This is up nearly 65.38 percent from its previous closing price of $9.07. Analysts expect Aurinia Pharmaceuticals Inc. stock to reach the higher price of $15.00, while the lowest price estimate is $12.00. However, 8 analysts have rated AUPH stock as an Overweight in their predictions for 2023.